Results 151 to 160 of about 1,100,787 (194)
Some of the next articles are maybe not open access.

Resistance to Bruton Tyrosine Kinase Inhibitors

Hematology/Oncology Clinics of North America
Targeting Bruton tyrosine kinase (BTK) has revolutionized the therapy for chronic lymphocytic leukemia. As patients remain on therapy, however, resistance develops progressively over time. The most common mechanism of resistance to covalent BTK inhibitors is mutation of the C481 target residue to serine, abrogating covalent binding.
openaire   +2 more sources

Inhibitors of Bruton's tyrosine kinase

2010
BERTHEL STEVEN   +9 more
  +16 more sources

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

European Journal of Medicinal Chemistry, 2021
Tian-tai Zhang, Dongmei Wang
exaly  

Home - About - Disclaimer - Privacy